- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.03. | FDA approves Novo Nordisk's Wegovy for cardiovascular risk reduction | ||
| 08.03. | iOnctura receives orphan drug status for pancreatic cancer therapy | ||
| 07.03. | Sionna Therapeutics secures $182m for cystic fibrosis drug development | ||
| 06.03. | UK NICE recommends GSK's Dostarlimab regimen for womb cancer | ||
| 05.03. | FDA approves Formosa-AimMax's post-surgery eye care treatment | ||
| 04.03. | EMA validates Daiichi Sankyo-AstraZeneca's cancer therapy applications | ||
| 01.03. | Kenai secures funds for neurological cell therapy development | ||
| 29.02. | SN Bioscience's SNB-101 received FDA orphan drug designation | ||
| 28.02. | Merck KGaA to open new distribution centre in Brazil for Life Science sector | ||
| 27.02. | Baseimmune secures funding for vaccine development | ||
| 26.02. | EMA CHMP provides positive opinion for Janssen's multiple myeloma therapy | ||
| 23.02. | FDA grants fast track status to Artiva's AlloNK for lupus nephritis | ||
| 22.02. | FDA accepts Servier's NDA review for glioma treatment | ||
| 21.02. | IsomAb secures funds to advance peripheral arterial disease treatment | ||
| 20.02. | Everest Medicines to terminate deal with Providence for mRNA platform | ||
| 19.02. | FDA grants breakthrough therapy status for Otsuka's IgAN drug | ||
| 16.02. | Japan grants priority review for Astellas' urothelial cancer regimen | ||
| 15.02. | Atara submits IND application to FDA for CAR T-cell therapy | ||
| 14.02. | ProfoundBio secures $112m to advance ADC portfolio for cancer | ||
| 13.02. | Precision receives payments from TG Therapeutics for azer-cel | ||
| 12.02. | FDA grants orphan drug designation for Disc's PV treatment | ||
| 09.02. | Aizon secures funds to accelerate development pipeline | ||
| 08.02. | Samsung Biologics and LegoChem enter ADC development deal | ||
| 07.02. | NIH grants $9m for nicotine cessation drug development | ||
| 06.02. | Exicure and Bluejay sign hepatitis treatment development deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
